We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
Thank you for submitting your question. You will get a reply within two business days to the email you provided. Thank you.
Active, Not Recruiting
An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread - CA209-142
Updated: 4 November, 2019 | ClinicalTrials.gov
This clinical trial is now complete.
For clinical trial results please visit ClinicalTrials.gov.
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information